Pulmonx Projects $90M-$92M Revenue for 2026
LUNG sits 20% above its 52-week low of $1.31.
Summary
Pulmonx Corp has issued its revenue guidance for 2026, projecting sales to be in the range of $90 million to $92 million. This forward-looking financial information is a critical input for investors and analysts to update their models and assess the company's growth trajectory. For a company of Pulmonx's size, this guidance provides a material outlook on its operational performance and market penetration. Traders will closely evaluate this projection against any existing consensus estimates to gauge potential stock price movements. Future updates on product pipeline and market adoption will be key factors to monitor.
At the time of this announcement, LUNG was trading at $1.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.4M. The 52-week trading range was $1.31 to $8.72. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.